Cargando…

Insulin Receptor in Pancreatic Cancer—Crown Witness in Cross Examination

SIMPLE SUMMARY: Pancreatic cancer (PDAC) is a highly malignant disease with low survival rates. Due to its close proximity to the insulin producing pancreatic islets, PDAC should be exposed to comparatively higher concentrations of the growth promoting hormone insulin. We wanted to know if PDAC migh...

Descripción completa

Detalles Bibliográficos
Autores principales: Heckl, Steffen M., Kercher, Lukas, Abdullazade, Samir, Schneider, Carolin, Krüger, Sandra, Behrens, Hans-Michael, Sebens, Susanne, Schäfer, Heiner, Schreiber, Stefan, Röcken, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508431/
https://www.ncbi.nlm.nih.gov/pubmed/34638472
http://dx.doi.org/10.3390/cancers13194988
_version_ 1784582095809544192
author Heckl, Steffen M.
Kercher, Lukas
Abdullazade, Samir
Schneider, Carolin
Krüger, Sandra
Behrens, Hans-Michael
Sebens, Susanne
Schäfer, Heiner
Schreiber, Stefan
Röcken, Christoph
author_facet Heckl, Steffen M.
Kercher, Lukas
Abdullazade, Samir
Schneider, Carolin
Krüger, Sandra
Behrens, Hans-Michael
Sebens, Susanne
Schäfer, Heiner
Schreiber, Stefan
Röcken, Christoph
author_sort Heckl, Steffen M.
collection PubMed
description SIMPLE SUMMARY: Pancreatic cancer (PDAC) is a highly malignant disease with low survival rates. Due to its close proximity to the insulin producing pancreatic islets, PDAC should be exposed to comparatively higher concentrations of the growth promoting hormone insulin. We wanted to know if PDAC might take advantage of this circumstance. Therefore we cross examined the insulin receptor’s (IR) role in PDAC and precursor lesions and put it into context with the expression of the insulin-like growth factor 1 receptor (IGF1R). Our study of 160 PDAC patient samples showed that IR overexpression is already present at the precursor level. IR overexpression in PDAC was associated with adverse clinical features. The IGF1R was found to play a different role than formerly assigned. We hypothesize that the close proximity to the pancreatic islets is exploited by PDAC up to the point of the islets’ ultimate destruction by local cancer growth. ABSTRACT: Background: The proximity of pancreatic cancer (PDAC) to the physiological source of the growth promoting hormone insulin might be exploited by this highly malignant cancer entity. We investigated if (I) PDACs express the insulin receptor (IR) in cancer cells and cancer vasculature, (II) if IR correlates with clinicopathological patient characteristics, including survival, and hence is involved in PDAC biology, (III) if IR is already expressed in precursor lesions, if (IV) the IGF1 receptor (IGF1R) is associated with clinicopathological patient characteristics and survival and (V) is linked to IR expression. Methods: 160 PDAC samples were examined for IR and IGF1R expression by immunohistochemistry. A modified HistoScore was correlated with clinicopathological characteristics and survival. Results: IR overexpression was already observed in pancreatic intraepithelial neoplasia. Furthermore, it was more frequently observed in advanced disease and associated with distant metastasis, UICC stage, lymphatic invasion and an increased lymph node ratio, but without impacting survival in the end. IGF1R expression was not associated with clinicopathological parameters or survival, in contrast to former paradigms. Conclusions: We hypothesize that the close proximity to the pancreatic islets might be advantageous for cancer growth at first, but it experiences self-limitation due to surgical removal or local destruction following accelerated cancer growth.
format Online
Article
Text
id pubmed-8508431
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85084312021-10-13 Insulin Receptor in Pancreatic Cancer—Crown Witness in Cross Examination Heckl, Steffen M. Kercher, Lukas Abdullazade, Samir Schneider, Carolin Krüger, Sandra Behrens, Hans-Michael Sebens, Susanne Schäfer, Heiner Schreiber, Stefan Röcken, Christoph Cancers (Basel) Article SIMPLE SUMMARY: Pancreatic cancer (PDAC) is a highly malignant disease with low survival rates. Due to its close proximity to the insulin producing pancreatic islets, PDAC should be exposed to comparatively higher concentrations of the growth promoting hormone insulin. We wanted to know if PDAC might take advantage of this circumstance. Therefore we cross examined the insulin receptor’s (IR) role in PDAC and precursor lesions and put it into context with the expression of the insulin-like growth factor 1 receptor (IGF1R). Our study of 160 PDAC patient samples showed that IR overexpression is already present at the precursor level. IR overexpression in PDAC was associated with adverse clinical features. The IGF1R was found to play a different role than formerly assigned. We hypothesize that the close proximity to the pancreatic islets is exploited by PDAC up to the point of the islets’ ultimate destruction by local cancer growth. ABSTRACT: Background: The proximity of pancreatic cancer (PDAC) to the physiological source of the growth promoting hormone insulin might be exploited by this highly malignant cancer entity. We investigated if (I) PDACs express the insulin receptor (IR) in cancer cells and cancer vasculature, (II) if IR correlates with clinicopathological patient characteristics, including survival, and hence is involved in PDAC biology, (III) if IR is already expressed in precursor lesions, if (IV) the IGF1 receptor (IGF1R) is associated with clinicopathological patient characteristics and survival and (V) is linked to IR expression. Methods: 160 PDAC samples were examined for IR and IGF1R expression by immunohistochemistry. A modified HistoScore was correlated with clinicopathological characteristics and survival. Results: IR overexpression was already observed in pancreatic intraepithelial neoplasia. Furthermore, it was more frequently observed in advanced disease and associated with distant metastasis, UICC stage, lymphatic invasion and an increased lymph node ratio, but without impacting survival in the end. IGF1R expression was not associated with clinicopathological parameters or survival, in contrast to former paradigms. Conclusions: We hypothesize that the close proximity to the pancreatic islets might be advantageous for cancer growth at first, but it experiences self-limitation due to surgical removal or local destruction following accelerated cancer growth. MDPI 2021-10-05 /pmc/articles/PMC8508431/ /pubmed/34638472 http://dx.doi.org/10.3390/cancers13194988 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Heckl, Steffen M.
Kercher, Lukas
Abdullazade, Samir
Schneider, Carolin
Krüger, Sandra
Behrens, Hans-Michael
Sebens, Susanne
Schäfer, Heiner
Schreiber, Stefan
Röcken, Christoph
Insulin Receptor in Pancreatic Cancer—Crown Witness in Cross Examination
title Insulin Receptor in Pancreatic Cancer—Crown Witness in Cross Examination
title_full Insulin Receptor in Pancreatic Cancer—Crown Witness in Cross Examination
title_fullStr Insulin Receptor in Pancreatic Cancer—Crown Witness in Cross Examination
title_full_unstemmed Insulin Receptor in Pancreatic Cancer—Crown Witness in Cross Examination
title_short Insulin Receptor in Pancreatic Cancer—Crown Witness in Cross Examination
title_sort insulin receptor in pancreatic cancer—crown witness in cross examination
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508431/
https://www.ncbi.nlm.nih.gov/pubmed/34638472
http://dx.doi.org/10.3390/cancers13194988
work_keys_str_mv AT hecklsteffenm insulinreceptorinpancreaticcancercrownwitnessincrossexamination
AT kercherlukas insulinreceptorinpancreaticcancercrownwitnessincrossexamination
AT abdullazadesamir insulinreceptorinpancreaticcancercrownwitnessincrossexamination
AT schneidercarolin insulinreceptorinpancreaticcancercrownwitnessincrossexamination
AT krugersandra insulinreceptorinpancreaticcancercrownwitnessincrossexamination
AT behrenshansmichael insulinreceptorinpancreaticcancercrownwitnessincrossexamination
AT sebenssusanne insulinreceptorinpancreaticcancercrownwitnessincrossexamination
AT schaferheiner insulinreceptorinpancreaticcancercrownwitnessincrossexamination
AT schreiberstefan insulinreceptorinpancreaticcancercrownwitnessincrossexamination
AT rockenchristoph insulinreceptorinpancreaticcancercrownwitnessincrossexamination